Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

July 12, 2021

FDA clears IND for ASC-618 gene therapy for hemophilia A

July 8, 2021

Shenzhen Salubris Pharmaceuticals patents factor XIa inhibitors

June 30, 2021

Keros reports preliminary phase II data on KER-050 for MDS

June 23, 2021

Etavopivat improves hematologic and hemolytic parameters in patients with sickle cell disease

June 21, 2021

Shenzhen Salubris Pharmaceuticals synthesizes FXIa inhibitors

June 16, 2021

BT-200: prolonging half-life of vWF

June 15, 2021

Preliminary phase I results reported for OMS-906

June 10, 2021

FDA lifts clinical hold on studies of LentiGlobin in sickle cell disease and beta-thalassemia

June 8, 2021

SPK-10000, a liver-targeted gene therapy for the treatment of hereditary angioedema

June 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...